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A systematic review 
and meta‑analysis of obesity 
and COVID‑19 outcomes
Xinya Zhang1,2,3, Alexander M. Lewis2,3, John R. Moley1,3 & Jonathan R. Brestoff1* 
Some studies report that obesity is associated with more severe symptoms following SARS‑
CoV‑2 infection and worse COVID‑19 outcomes, however many other studies have not reproduced 
these findings. Therefore, it is uncertain whether obesity is in fact associated with worse COVID‑
19 outcomes compared to non‑obese individuals. We conducted a systematic search of PubMed 
(including MEDLINE) and Google Scholar on May 18, 2020 to identify published studies on COVID‑19 
outcomes in non‑obese and obese patients, covering studies published during the first 6 months of 
the pandemic. Meta‑analyses with random effects modeling was used to determine unadjusted odds 
ratios (OR) and 95% confidence intervals (CI) for various COVID‑19 outcomes in obese versus non‑
obese patients. By quantitative analyses of 22 studies from 7 countries in North America, Europe, 
and Asia, we found that obesity is associated with an increased likelihood of presenting with more 
severe COVID‑19 symptoms (OR 3.03, 95% CI 1.45–6.28, P = 0.003; 4 studies, n = 974), developing 
acute respiratory distress syndrome (ARDS; OR 2.89, 95% CI 1.14–7.34, P = 0.025; 2 studies, n = 96), 
requiring hospitalization (OR 1.68, 95% CI 1.14–1.59, P < 0.001; 4 studies, n = 6611), being admitted 
to an intensive care unit (ICU; OR 1.35, 95% CI 1.15–1.65, P = 0.001; 9 studies, n = 5298), and 
undergoing invasive mechanical ventilation (IMV; OR 1.76, 95% CI 1.29–2.40, P < 0.001; 7 studies, 
n = 1558) compared to non‑obese patients. However, obese patients had similar likelihoods of death 
from COVID‑19 as non‑obese patients (OR 0.96, 95% CI 0.74–1.25, P = 0.750; 9 studies, n = 20,597). 
Collectively, these data from the first 6 months of the pandemic suggested that obesity is associated 
with a more severe COVID‑19 disease course but may not be associated with increased mortality.
In the first 6 months of human exposure to Severe Acute Respiratory Syndrome (SARS)-Coronavirus-2 (SARS-
CoV-2), which causes Coronavirus Disease 2019 (COVID-19), there were over 9,000,000 confirmed infections 
and nearly 500,000 deaths  worldwide1. By the end of 2020, it is estimated that there were more than 81 million 
confirmed cases of COVID-19 and over 1.7 million  deaths1. Several risk factors have been associated with 
developing more severe COVID-19 and increased risk of death, including age over 65 years, type 2 diabetes 
(T2DM), and cardiovascular disease (CVD)2–4. Emerging studies have also suggested that obesity is associated 
with worse COVID-19 outcomes, including increased rates of hospitalization and intensive care unit (IUC) 
admission, invasive mechanical ventilation (IMV), and  death5–12. However, many studies have not reproduced 
these  findings13–22. In addition, some studies have reported that patients with severe COVID-19 have similar 
or slightly increased body mass index (BMI) compared to patients with non-severe  disease23–25. Therefore, it is 
unclear whether obesity is in fact associated with adverse COVID-19 outcomes or death.
To investigate this, we performed a systematic search of PubMed (including MEDLINE) and Google Scholar 
on May 18, 2020 to identify all published studies that report COVID-19 comorbidities or outcomes during the 
first ~ 6 months of the pandemic. We identified 22 cohort studies from 7 countries that could be included in 
quantitative meta-analyses for six outcomes in obese versus non-obese patients. Our meta-analyses revealed that 
obese patients are more likely than non-obese patients to present with severe disease, to develop ARDS, need 
hospitalization, be admitted to the ICU, or require IMV. Surprisingly, however, obesity was not associated with 
an increased risk of death from COVID-19. Subgroup analysis by continent suggested that in Europe, obesity 
might be associated with lower mortality from COVID-19 compared to non-obese patients. Although these 
meta-analyses provide unadjusted odds ratio (OR) estimates, these data from the first 6 months of the pandemic 
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suggest that obesity is associated with a more severe disease course but does not appear to be linked to increased 
mortality from COVID-19.
Results
Literature search and characteristics of the included studies. Systematic searches of PubMed 
(including MEDLINE) and Google Scholar returned 589 records that were reviewed by 2 independent investiga-
tors (Fig. 1A). There were 12 additional records identified from reviewing the reference lists of full-text articles 
we assessed for eligibility (see below). This resulted in 584 unique records after duplicates were removed. We 
excluded 404 records based on manual review of titles for any potential relevance and the article type (e.g. narra-
tive reviews). Of the remaining 180 records, we read the abstracts and excluded 52 records based on no potential 
relevance. For the remaining 128 studies, we obtained the full text articles which were reviewed in three rounds. 
In the first round, two independent investigators identified all studies that stratified any COVID-19 comorbidity 
or outcome on obesity or BMI category. In the second round, a third investigator independently reviewed all of 
the excluded full text articles to prevent error. In the third round, four authors met in a virtual consensus confer-
ence to review all studies with potential for inclusion. For each study that was included, we scanned the refer-
Figure 1.  Systematic search strategy and COVID-19 outcomes reported in association with obesity. (A) 
PRISMA Flow Diagram showing the numbers of articles per stage of review, resulting in n = 22 full text articles 
reporting COVID-19 outcomes stratified on obesity status. (B) Six outcomes were reported by the 22 studies 
included in meta-analysis. The numbers of contributing articles per outcome are in parentheses. Numbers do 
not add to 22 because some studies report more than one outcome. (C) World map showing the locations where 
the included studies were conducted. The image was generated in BioRender with permission to publish.
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ence list which resulted in identification of 12 additional full text articles (128 articles total) that we reviewed in 
conference. Overall, we excluded 106 full text articles (of 128) because they did not report original COVID-19 
outcome data stratified on obesity or BMI category (n = 63), provided insufficient data to include in the meta-
analysis (n = 29), or were not a cohort study (n = 14).
This resulted in a total of 22 articles that were included in the meta-analysis (Fig. 1A)5,6,8–22,26–30. There were 
6 outcomes that were reported by at least 2 of these 22 studies: severity (4 studies representing n = 974 patients), 
acute respiratory distress syndrome (ARDS, 2 studies representing n = 96 patients), hospitalization (4 studies 
representing n = 6611 patients), invasive mechanical ventilation (IMV, 7 studies representing n = 1558 patients), 
being admitted to an intensive care unit (ICU, 8 studies representing n = 5298 patients), and death (9 studies 
representing n = 20,597 patients) (Fig. 1B). Geographically, these studies were distributed across 3 continents 
(Fig. 1C). Nine studies were from North America (United States only), 7 studies were from Europe (2 Italy, 2 
France, 2 United Kingdom, and 1 Germany), and 6 studies were from Asia (5 China and 1 Singapore). The char-
acteristics of these 22 studies are summarized in Table 1. Study quality was assessed using the Newcastle–Ottawa 
Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses, the results of which are pro-
vided in Supplemental Table S1. This scoring system assigns stars (up to 9 maximum) for meeting specific quality 
metrics relating to cohort selection, comparability, and the outcome, where more stars indicates higher quality. 
The majority of the studies achieved 6 or 7 stars. Four studies received 5 stars, and two studies received 8 stars.
Obesity is associated with a more severe COVID‑19 disease course. To investigate the association 
between obesity and COVID-19 severity, we performed meta-analyses on each outcome variable. Of the four 
studies that reported non-severe versus severe disease, three reported a statistically significant increase in disease 
severity in obese patients compared to non-obese patients with ORs ranging from 1.28 to 6.9014,28,30, whereas one 
study did not report a statistically significant  difference27. On average, random effects meta-analysis modeling 
indicated an overall OR 3.03 (95% CI 1.46–6.28, P = 0.003), indicating that the 4 studies collectively support an 
association between obesity and exhibiting more severe COVID-19 disease (Fig. 2A).
Consistent with this observation, there were 2 studies that compared the likelihood of developing ARDS in 
obese versus non-obese  patients15,26. Although both studies reported a trend towards an increased likelihood 
of developing ARDS, neither study alone was statistically significant, likely due to being underpowered. When 
combined in a meta-analysis with random effects modeling, we found that there was a statistically significant 
association between obesity and developing ARDS (OR 2.89, 95% CI 1.14–7.35, P = 0.025) (Fig. 2B). This finding 
also supports a relationship between obesity and more severe COVID-19.
From a clinical practice perspective, patients with severe respiratory disease are the most likely to be admit-
ted to the hospital for acute or intensive care. We identified 4 studies that reported on hospitalization rates in 
obese versus non-obese  patients5,12,18,19. Each of these studies reported a statistically significant increase in the 
likelihood of hospitalization for obese patients with COVID-19, with ORs ranging from 1.39 to 2.67. In meta-
analysis with random effects modeling, the overall OR for hospitalization in obese versus non-obese patients 
was 1.68 (95% CI 1.28–2.19, P < 0.001) (Fig. 2C).
A subset of COVID-19 patients develop severe respiratory failure that necessitates invasive mechanical ven-
tilation (IMV). There were seven studies that reported IMV in obese and non-obese patients with COVID-19. 
Of these, two reported a significant increase in the likelihood of IMV in obese versus non-obese  patients8,10, and 
a third reported a similar observation with a non-significant P  value19. The other four studies did not report a 
statistically significant association between obesity and  IMV13–15,17. Collectively, however, random effects meta-
analysis revealed an overall significant increase in the likelihood of IMV in obese versus non-obese patients with 
an OR 1.76 (95% CI 1.29–2.40, P < 0.001) (Fig. 3A).
There were 8 studies that reported ICU admission rates stratified by obesity. Two of these studies reported 
a statistically significant increase in the likelihood of ICU admission in obese versus non-obese  patients6,9. The 
other six studies did not report a statistically significant increase in ICU admission rates in obese  patients13–18, 
however all of them reported OR > 1.0 and 5 were likely underpowered to detect a significant difference. When 
analyzed together in meta-analysis with random effects modeling, overall there was a statistically significant 
increase in the likelihood of ICU admission in obese versus non-obese patients with an OR 1.35 (95% CI 
1.14–1.59, P < 0.001) (Fig. 3B).
Obesity does not appear to be associated with increased COVID‑19‑associated mortal‑
ity. There were 9 studies that reported obesity-stratified mortality rates. One relatively small study reported 
a statistically significant increase in the likelihood of mortality in obese patients with cardiovascular disease 11. 
In contrast, one large study of ICU patients reported a significant decrease in the death rates in obese patients 
compared to non-obese  patients29. The other 7 studies did not report a statistically significant unadjusted likeli-
hood of death in obese versus non-obese patients, with OR ranging from 0.39 to 4.2513–15,17,20–22. Surprisingly, in 
meta-analysis with random effects modeling, there was no statistically significant association between obesity 
and the likelihood of death from COVID-19 with an overall OR 0.96 (95% CI 0.74–1.25, P = 0.750) (Fig. 4A).
To assess whether there was a geographic difference in obesity-associated death rates from COVID-19, we 
performed a subgroup analysis by continent. Two studies from North America (United States) did not show an 
association between obesity and mortality with an OR 0.95 (95% CI 0.70–1.28, P = 0.725) (Fig. 4B). A similar 
finding was observed in the Asian studies (China and Singapore), where the OR for death in obese versus non-
obese patients was 4.24 (95% CI 0.30–59.03, P = 0.283) (Fig. 4C). In contrast, in the European studies (United 
Kingdom and Italy), obesity was associated with a significantly lower likelihood of death, with an OR 0.86 (95% 
CI 0.74–0.99, P = 0.031) (Fig. 4D).
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Table 1.  Study characteristics. RC, retrospective cohort; PC, prospective cohort; n/a, not applicable; Incl., 
included; BMI, body mass index; y, years; NR, not reported; IQR, interquartile range; SD, standard deviation; 
S, severity; ARDS, acute respiratory distress syndrome; H, hospitalization; W, ward; OP, outpatient; ICU, 
intensive care unit admission; IMV, invasive mechanical ventilation; D, death; N, none; HF, heart failure; DM2, 
type 2 diabetes mellitus; CVD, cardiovascular disease; Meds, medications; Abx, antibiotics; AVT, antiviral 
therapy; HC, hydroxychloroquine; Z, azithromycin; CS, corticosteroids; ACEi, angiotensin converting enzyme 
II inhibitor; ARB, angiotensin II receptor blocker.
Author, year Location Study type n Incl. (n) Excluded (n) Excluded reason
Ages included 
(y) Age (y) Obesity (kg/m2)
Extractable 
outcome (s) Sex Ethnicity Study setting SES
Pre-existing 
conditions Meds
Busetto et al.13 Padova, Italy RC 92 92 0 n/a 40–96
Mean 70.5 (SD 
13.3)











RC 383 383 0 n/a  ≥ 18 NR BMI ≥ 28 IMV, ICU, S, D
Male and 
female
Asian W NR NR NR





New York, NY, 
USA









White 1 (3%), 
Black 3 (9.1%), 
Latino 26 
(78.8%), Other 3 
(9.1%)
OP, W, ICU NR NR NR

















RC 50 50 0 n/a NR
Median 65 
(IQR 58–76)
BMI ≥ 30 ARDS
Male and 
female
NR W, ICU NR DM2 (58%) NR
Goyal et al.10
New York, NY, 
USA











W NR DM2 (25.2%) NR
Hu et al.27 Wuhan, China RC 323 294 29 BMI Unknown 23–91 Median 62 BMI ≥ 30 S
Male and 
female
Asian W NR NR AVT, Abx, CS
Huang et al.28 Jiansu, China RC 202 172 30 BMI unknown NR
Median 44 
(IQR 33–54)
BMI ≥ 28 S
Male and 
female
Asian W NR NR NR






















RC 103 103 0 n/a  ≥ 18
Median 60 
(52–70)















RC 531 436 95 BMI unknown  ≥ 18
Median 61 (no 
IQR shown)






Other 17 (3.3%), 
Unknown 82 
(15.4%)
OP, W NR DM2 (25.5%) NR
Lighter et al.9
New York, NY, 
USA
RC 3615 1762 0 n/a NR NR BMI ≥ 30 ICU NR NR W NR NR NR
Moriconi et al.21 Pisa, Italy RC 100 100 0 n/a NR NR BMI ≥ 30 D
Male and 
female
NR W NR NR NR
Ong et al.17
Tan Tock Seng, 
Singapore
RC 182 91 91 BMI unknown NR NR BMI ≥ 25 IMV, ICU, D
Male and 
female




RC 112 112 0 BMI unknown  ≥ 18
Median 62 
(IQR 55–67)
BMI ≥ 25 D
Male and 
female
Asian W NR CVD ACEI/ARB
Petrilli et al.5
New York, NY, 
USA
RC 5279 5040 239 BMI unknown  ≥ 19
Median 54 
(IQR 38–66)













OP, W NR DM2 (22.6%) NR
Rosenberg et al.22
New York, NY, 
USA









W NR DM2 (48.9%) HC or Z
Simonnet et al.8 Lille, France RC 124 124 0 n/a NR
Median 60 
(IQR 51–70)
BMI ≥ 30 IMV
Male and 
female
NR ICU NR DM2 (23%) NR
Suleyman et al.18 Detroit, MI, USA RC 463 463 0 n/a NR
Mean 57.5 (SD 
16.8)
Assumed 










W, ICU NR DM2 (38.4%) Abx
Toussie et al.19
New York, NY, 
USA
RC 338 313 25 BMI unknown 21–50
Median 39 
(IQR 31–45)
BMI ≥ 30 IMV, H
Male and 
female
White 71 (21%), 
Asian 30 (9%), 




OP, W NR NR NR
Zheng et al.30 Wenzhou, China RC 66 66 0 n/a 18–75
Mean 47 (no 
SD shown)
BMI ≥ 25 S
Male and 
female
Asian W NR DM2 (24.2%)
COVID-19 
Management 
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It is known that COVID-19 can result in death over a period of several weeks and that recovery can take up 
to 6–8 weeks or  longer31. We hypothesized that the sampling interval for the studies might relate to death rates. 
To assess this, we calculated the sampling interval for each study as the number of days between the start of 
enrollment and the end of follow-up. One  study17 did not report sufficient information to determine the sampling 
interval and therefore was not included in this analysis. The sampling interval ranged from 20 to 89 days with 
a mean ± standard error of the mean of 50.3 ± 10.3 days and a median (interquartile range) of 36 (27.75–85.0) 
days. We did not observe a statistically significant relationship between the sampling interval and the OR for 
death (Supplemental Figure S1).
Sensitivity analyses. To determine whether the overall OR and 95% CI were driven by any individual 
study, we performed remove-one sensitivity analyses for each outcome, in which each study is removed from 
the analysis and a new overall OR (95% CI) is computed. For COVID-19 disease severity (Supplemental Figure 
S2A), hospitalization (Supplemental Figure S2B), ICU admission (Supplemental Figure S2C), and IMV (Sup-
plemental Figure S2D), removing any one study had no appreciable effect on the OR effect size or P value of 
the overall association. Remove-one analyses were not computed for ARDS because there were only two studies 
contributing to that analysis. For death (Supplemental Figure S2E), removing any one study also had no effect on 
the OR (95% CI), except for one study by Peng et al. Removing this study from the dataset resulted in a statisti-
cally significant decrease in mortality in obese patients compared to non-obese patients, with a remove-one OR 
0.86 (95% CI 0.78–0.95, P = 0.003).
Publication bias. We performed publication bias analyses and, for each outcome, did not find evidence 
of publication bias (Supplemental Figure S3). Fail-safe N tests were performed to determine the number of 
additional studies with OR = 0 that would be needed to abolish statistical significance for each outcome’s meta-
analysis (Supplemental Table S2). For ARDS, the fail-safe N statistic was not calculable. For death, we did not 
observe a statistically significant effect, therefore the fail-safe N was 0. For the other outcomes, the fail-safe N 
was greater than the number of studies observed in the meta-analyses. We acknowledge that the fail-safe N test 
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Chao et al., 2020 3.000 0.703 12.803 1.484 0.138 41.23
Dreher et al., 2020 2.821 0.837 9.509 1.672 0.094 58.77
2.893 1.140 7.345 2.235 0.025
0.01 0.1 1 10 100
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Cai et al., 2020 2.278 1.157 4.487 2.381 0.017 36.61
Hu et al., 2020 1.282 0.409 4.016 0.426 0.670 23.13
Huang et al., 2020 6.900 2.381 19.997 3.558 0.000 25.00
Zheng et al., 2020 5.768 1.192 27.911 2.178 0.029 15.26
3.032 1.464 6.281 2.985 0.003
0.01 0.1 1 10 100
B Acute respiratory distress syndrome
A Severity
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Killerby et al., 2020 1.692 1.157 2.472 2.714 0.007 22.65
Petrilli et al., 2020 1.385 1.234 1.555 5.539 0.000 38.88
Suleyman et al., 2020 1.560 1.012 2.404 2.013 0.044 19.91
Toussie et al., 2020 2.671 1.683 4.237 4.171 0.000 18.57
1.676 1.284 2.188 3.801 0.000
0.01 0.1 1 10 100
C Hospitalization
Figure 2.  Obesity is associated with more severe COVID-19 and an increased likelihood of acute respiratory 
distress syndrome (ARDS) and hospitalization. Random effects meta-analyses of odds ratios (OR) and 95% 
confidence intervals (CI) in obese versus non-obese patients for (A) presenting with severe COVID-19 disease 
(4 studies, n = 915 patients), (B) developing acute respiratory distress syndrome (ARDS) (2 studies, n = 96 
patients), and (C) being hospitalized (4 studies, n = 6,252 patients). Non-obese is defined as the reference group.
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has significant limitations, including but not limited to its focus on P values and its lack of consideration of study 
characteristics such as study size, quality, and design. Though publication bias cannot be formally ruled out, 
both funnel plot and fail-safe N test analyses do not support evidence of publication bias in this meta-dataset.
Discussion
Using a systemic search strategy and subsequent meta-analysis of 22 studies representing n = 30,141 patients from 
7 countries, we show that obesity is significantly associated with several adverse comorbidities and outcomes 
from COVID-19. Specifically, obese patients are approximately 3-times more likely to present with severe disease 
or develop ARDS, 1.7 times more likely to be hospitalized, 1.3 times more likely to be admitted to the ICU, and 
1.7 times more likely to require IMV. Despite this more severe disease course, obesity was not associated with 
increased mortality from COVID-19. These data indicate that although obesity is associated with more severe 
COVID-19 and disease progression, paradoxically these associations do not appear to result in an increased 
risk of death.
It is not yet known why obese patients develop more severe COVID-19. One possible explanation is that 
obese patients express higher levels of viral entry factors. Supporting this idea are studies indicating that obesity 
is associated with increased expression of ACE2, a receptor for SARS-CoV-2 that is required for viral  entry32, 
in the human lung bronchial epithelium and other potentially relevant organs such as pericardial adipose 
 tissue33,34. These observations suggest that obese patients may have increased susceptibility to SARS-CoV-2 
infection. Another possible explanation is that obese patients exhibit chronic pulmonary inflammation, which 
has previously been linked to an increased risk of developing inflammatory lung diseases and more severe viral 
 pneumonia35–38. A third reason that obese patients might exhibit more severe COVID-19 is the effect of obesity 
on pulmonary mechanics and lung function. Obesity leads to a heavier chest wall that promotes hypoventilation 
and has been shown to decrease lung compliance and increase lung  resistance39–41. These physiological param-
eters may increase the susceptibility of obese patients to develop respiratory failure in the setting of SARS-CoV-2 
infection. Further research is needed to investigate these possibilities.
It is not clear why obesity is associated with more severe COVID-19 without being linked to an increase in 
mortality in our meta-analyses. Our data are restricted to the first 6 months of the pandemic and therefore rep-
resent only the first datasets published on mortality in obese and non-obese patients. Subsequently, there have 
been several large cohort  studies42–44 that have identified an increased risk in mortality in obese patients infected 
with SARS-CoV-2, and these studies and likely other relevant studies were not included in our meta-analyses 
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Busetto et al., 2020 1.228 0.499 3.018 0.447 0.655 3.46
Cai et al., 2020 1.444 0.527 3.957 0.715 0.474 2.76
Caussy et al., 2020 2.055 1.238 3.412 2.784 0.005 10.88
Chao et al., 2020 1.667 0.430 6.460 0.739 0.460 1.52
Kalligeros et al., 2020 1.919 0.870 4.232 1.615 0.106 4.47
Lighter et al., 2020 1.264 1.016 1.573 2.104 0.035 58.66
Ong et al., 2020 1.029 0.416 2.544 0.061 0.951 3.41
Suleyman et al., 2020 1.192 0.772 1.841 0.792 0.428 14.83
1.346 1.139 1.591 3.481 0.000
0.01 0.1 1 10 100
B ICU admission
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Busetto et al., 2020 0.593 0.115 3.046 -0.626 0.531 3.57
Cai et al., 2020 1.444 0.527 3.957 0.715 0.474 9.41
Chao et al., 2020 1.167 0.188 7.252 0.165 0.869 2.86
Goyal et al., 2020 1.640 1.058 2.541 2.214 0.027 49.85
Ong et al., 2020 1.344 0.456 3.963 0.535 0.592 8.17
Simonnet et al., 2020 3.302 1.456 7.488 2.860 0.004 14.26
Toussie et al., 2020 2.375 0.969 5.821 1.891 0.059 11.89
1.758 1.291 2.395 3.577 0.000
0.01 0.1 1 10 100
A Invasive mechanical ventillation
Figure 3.  Obesity is associated with an increased likelihood of requiring invasive mechanical ventilation (IMV) 
and admission to the intensive care unit (ICU) in the setting of COVID-19. Random effects meta-analyses of 
odds ratios (OR) and 95% confidence intervals (CI) in obese versus non-obese patients for (A) requiring IMV 
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because of the cut-off date for our search. In addition, there are several meta-analyses with later search dates 
than ours which do show an increased risk of mortality in obese COVID-19 patients. For example, Noor et al. 
(2020) includes 58 studies that were published since the beginning of the pandemic and showed a pooled risk 
ratio of 2.18 (95% confidence interval 1.10–4.34) for death in obese vs non-obese  patients45. Therefore, it is 
possible that the smaller number of studies in our meta-analysis and time frame of included studies led to type 
II error. However, if type II error did not occur in our meta-analyses and the association we report is correct, 
this raises the question of why obese patients do not have increased mortality despite more severe COVID-19. 
Obesity was associated with more severe disease but improved survival for viral pneumonias (not COVID-19)46, 
a phenomenon known as the obesity paradox, and there is little known about this phenomenon.
An important limitation of our study is that the analyses were not adjusted for other variables that may be 
related to obesity and COVID-19. Most of the available studies provided raw data on outcomes in obese vs 
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Busetto et al., 2020 0.393 0.080 1.920 -1.154 0.248 2.58
Cai et al., 2020 4.250 0.377 47.925 1.171 0.242 1.16
Chao et al., 2020 0.724 0.028 18.873 -0.194 0.846 0.65
Docherty et al., 2020 0.946 0.833 1.074 -0.858 0.391 31.29
ICNARC, 2020 0.799 0.727 0.877 -4.681 0.000 32.33
Moriconi et al.,  2020 0.778 0.254 2.382 -0.440 0.660 4.81
Ong et al., 2020 0.410 0.041 4.101 -0.758 0.448 1.28
Peng et al., 2020 32.083 6.728 152.999 4.352 0.000 2.66
Rosenberg et al., 2020 0.949 0.699 1.289 -0.335 0.737 23.25
0.958 0.735 1.249 -0.318 0.750
0.01 0.1 1 10 100
A Death - All
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Chao et al., 2020 0.724 0.028 18.873 -0.194 0.846 0.87
Rosenberg et al., 2020 0.949 0.699 1.289 -0.335 0.737 99.13
0.947 0.698 1.284 -0.352 0.725
0.01 0.1 1 10 100
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Cai et al., 2020 4.250 0.377 47.925 1.171 0.242 31.17
Ong et al., 2020 0.410 0.041 4.101 -0.758 0.448 31.99
Peng et al., 2020 32.083 6.728 152.999 4.352 0.000 36.84
4.237 0.304 59.028 1.074 0.283
0.01 0.1 1 10 100
Odds ratio and 95% CI
Odds Lower Upper Relative 
ratio limit limit Z-Value p-Value weight
Busetto et al., 2020 0.393 0.080 1.920 -1.154 0.248 0.78
Docherty et al., 2020 0.946 0.833 1.074 -0.858 0.391 44.56
ICNARC, 2020 0.799 0.727 0.877 -4.861 0.000 53.10
Moriconi et al., 2020 0.778 0.254 2.382 -0.440 0.660 1.55
0.856 0.743 0.986 -2.158 0.031
0.01 0.1 1 10 100
B Death - North America (United States)
C Death - Asia (China and Singapore)
D Death - Europe (Italy and United Kingdom)
Figure 4.  Obesity is not associated with increased COVID-19-associated mortality. Random effects meta-
analysis of odds ratios (OR) and 95% confidence intervals (CI) for the likelihood of death in obese vs non-obese 
COVID-19 patients (A) overall (9 studies, n = 20,597 patients and in studies from (B) North America (2 studies, 
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non-obese groups but did not provide results of multivariate (i.e., adjusted) analyses. Some studies did perform 
multivariate analyses to adjust for age, sex, ethnicity, and/or other variables, however variations in how these 
studies were performed and the outcomes they reported precluded us from conducting meta-analyses with mul-
tivariate models. A second limitation is that BMI category could not be taken into account in our meta-analyses. 
Most studies did not stratify COVID-19 outcome data by BMI category or reported different BMI category defini-
tions that precluded meta-analysis. It is possible that higher BMI categories (e.g. BMI > 45 kg/m2) are associated 
with increased or decreased risks of some outcomes compared to lower BMI categories (BMI 30–34.9 kg/m2). 
Third, the search date for this systematic review and meta-analysis was inclusive of studies published within the 
first ~ 6 months of the COVID-19 pandemic, some of which were relatively small or underpowered. It is possible 
that subsequent larger studies that enable careful adjustment for potential confounding variables could shift the 
landscape of published literature and could influence the presence and/or strength of associations reported in 
future meta-analyses.
In conclusion, our systematic review and meta-analyses revealed associations between obesity and COVID-
19 comorbidities and outcomes. Obesity appears to be associated with an increased likelihood of having more 
severe COVID-19, developing ARDS, being hospitalized, being admitted to the ICU, and requiring IMV. How-
ever, obesity does not appear to be associated with increased mortality from COVID-19, at least in unadjusted 
analyses of data published during the first 6 months of the pandemic. These results have direct implications for 
clinicians because body mass index and obesity status are readily obtainable data that can be used to identify 
patients at higher risk of a more severe COVID-19 disease course.
Methods
Search strategy and exclusion and inclusion criteria. This systematic review and meta-analysis 
followed PRISMA and MOOSE  Guidelines47,48. Three authors independently searched PubMed, MEDLINE 
(through PubMed), and Google Scholar on May 18, 2020 using the following Boolean search terms in the text 
field:
("COVID-19" OR COVID19 OR "SARS-CoV-2" OR "Severe acute respiratory syndrome coronavirus 2" OR 
"novel coronavirus" OR nCoV OR “coronavirus disease” or 2019-nCoV OR coronavirus) AND (obesity 
OR BMI OR "body mass index" OR diabetes OR "metabolic disease" OR "metabolic syndrome")
The search did not include a language, date, or other restriction. The search results from the two databases 
were merged and duplicates removed. Studies published in or prior to 2018 were then excluded because they 
could not theoretically directly relate to SARS-CoV-2 or COVID-19. The titles and article types of each remaining 
entry were manually reviewed by two investigators independently. Review articles, opinions, commentaries, and 
case reports were eliminated. For all remaining entries, two independent reviewers read all of the abstracts and 
excluded articles that did not mention obesity, BMI, a metabolic disease or that did not present any new data. 
Entries that did not include an abstract (e.g., Letter to the Editor) were not eliminated. Abstracts that were not 
in English were translated by a native speaker if in Chinese or using Google Translate if in another language. 
After screening titles and abstracts, n = 116 entries remained, and we obtained the full text for each. Two review-
ers independently evaluated each full text article to determine whether it reported any COVID-19 outcome or 
comorbidity stratified by obesity status or BMI category, and these articles were carried forward to the next stage 
of review. As an additional check, articles that were not carried forward and their reference lists were reviewed 
by a third independent investigator, who could carry forward any article for further review. In total, n = 128 full 
text articles were reviewed in a virtual conference call with screen sharing involving all investigators. The meth-
ods sections of full text articles were reviewed, and all study types other than cohort studies (retrospective or 
prospective) were excluded. Any disagreement was resolved by discussion and consensus among all authors. To 
identify any missed papers, we reviewed the reference lists for each study that was included in the quantitative 
synthesis. In total, n = 22 articles met inclusion criteria, and from these the reported COVID-19 outcomes were 
tallied. If two articles reported the same outcome, meta-analysis was performed.
Definition of obesity. The definition of obesity was BMI ≥ 30 kg/m2 for all studies, except for those from 
Asia, where obesity is typically defined based on lower BMI  cutoffs49. Definitions of obesity for each study are 
listed in Table 1.
Outcomes. The following outcomes were reported by at least two studies: severity of COVID-19 as defined 
by Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 5 or 7)50; ARDS as 
defined by the Berlin Definition  criteria51; admission to the hospital; admission to an IC; requirement for IMV; 
or death. For death, the sampling interval was defined as the start of enrollment to the end of the study’s follow-
up period.
Study quality assessment and data extraction. Each of the n = 22 included articles were presented 
in virtual conference with all authors present. The characteristics and quality of all studies were assessed using 
the Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses52. Data 
were extracted from each article by one investigator and checked by two other investigators independently. Since 
adjusted analyses were uncommon and did not use similar covariates, we performed our meta-analyses on unad-
justed odds ratios. For several  studies9,10,12,15,17–22,26, we used data contained with the relevant paper to calculate 
the numbers of patients in one group or to collapse obese categories into one obese group of BMI ≥ 30 and one 
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non-obese group of BMI < 30 (unless ethnicity-specific BMI cutoffs dictated use of a different cut off for obese 
vs non-obese, as described above).
Ethics. This systematic review and meta-analysis includes only anonymized summary data or statistics from 
previously published studies and therefore is exempt from Institutional Review Board (IRB) review or approval. 
However, all studies included in this meta-analysis were required to have declared that their relevant IRB or 
equivalent reviewed and approved the study.
Statistical analysis. Meta-analysis of each COVID-19 outcome was performed using the Comprehensive 
Meta-Analysis (CMA) Professional v3 (Engelwood, New Jersey, USA). Odds ratios (OR) and 95% confidence 
intervals (CI) were calculated by 2 × 2 tables and/or inverse variance approach and analyzed using a random 
effects model. The Q test was performed to assess the heterogeneity between studies. For meta-analyses with 
at least three contributing studies, sensitivity analyses were performed by removing one study at a time and 
comparing the all-included OR and 95% and the various all-minus-one ORs and 95% CIs. Publication bias was 
assessed in CMA by plotting each outcome variable’s log OR from each study against standard error. Fail-safe N 
tests were also performed in CMA. Prism 8 was used to relate the sampling interval and mortality OR via linear 
regression (GraphPad Software, LLC). Statistical significance was set at P < 0.05.
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